PMID- 23743723
OWN - NLM
STAT- MEDLINE
DCOM- 20131218
LR  - 20130607
IS  - 1746-6318 (Electronic)
IS  - 1746-630X (Linking)
VI  - 8
IP  - 4
DP  - 2013 Jul
TI  - Immune response to HIV.
PG  - 333-40
LID - 10.1097/COH.0b013e328361faf4 [doi]
AB  - PURPOSE OF REVIEW: Major advances have been made in the delineation of 
      HIV-specific immune response and in the mechanisms of virus escape. The kinetics 
      of the immunological and virological events occurring during primary HIV 
      infection indicate that the establishment of the latent HIV reservoir, the major 
      obstacle to HIV eradication likely occurs during the very early stages of primary 
      infection, that is, the 'eclipse phase', prior to the development of the 
      HIV-specific immune response which has limited efficacy in the control of the 
      early events of infection. Therefore, the window of opportunity to develop 
      effective interventions either to clear HIV during primary infection or to 
      prevent rebound of HIV in patients successfully treated who stop antiretroviral 
      therapy is very narrow. RECENT FINDINGS: Genetic factors most strongly associated 
      with nonprogressive infection are human leukocyte antigen (HLA) class I alleles 
      and particularly HLA-B5701. CD4 and CD8 T-cell responses with polyfunctional 
      profile are associated with nonprogressive infection. Broader neutralizing 
      antibodies are detected 3-4 years after infection, generated only in 20% of 
      individuals but show no efficacy in the control of HIV replication. SUMMARY: In 
      the present review, we shall discuss the different components of the HIV-specific 
      immune response elicited by the infection, the kinetics of these responses during 
      primary infection and the changes following transition to the chronic phase of 
      infection, and the functional profile of 'effective' versus 'noneffective' 
      HIV-specific immune responses.
FAU - Perreau, Matthieu
AU  - Perreau M
AD  - Division of Immunology and Allergy bSwiss Vaccine Research Institute, Centre 
      Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
FAU - Levy, Yves
AU  - Levy Y
FAU - Pantaleo, Giuseppe
AU  - Pantaleo G
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin HIV AIDS
JT  - Current opinion in HIV and AIDS
JID - 101264945
RN  - 0 (Antibodies, Viral)
SB  - IM
MH  - Antibodies, Viral/immunology
MH  - CD4-Positive T-Lymphocytes/immunology
MH  - CD8-Positive T-Lymphocytes/immunology
MH  - HIV Infections/*immunology
MH  - Humans
EDAT- 2013/06/08 06:00
MHDA- 2013/12/19 06:00
CRDT- 2013/06/08 06:00
PHST- 2013/06/08 06:00 [entrez]
PHST- 2013/06/08 06:00 [pubmed]
PHST- 2013/12/19 06:00 [medline]
AID - 01222929-201307000-00013 [pii]
AID - 10.1097/COH.0b013e328361faf4 [doi]
PST - ppublish
SO  - Curr Opin HIV AIDS. 2013 Jul;8(4):333-40. doi: 10.1097/COH.0b013e328361faf4.